Systematic dose-extension of octreotide LAR: The importance of individual tailoring of treatment in patients with acromegaly

Clinical Endocrinology

Volumn 61, Issue 2, 2004, Pages 224-231

  Turner, Helen E ^a   Thornton Jones, Viv A ^a   Wass, John A H ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; LONG ACTING DRUG; OCTREOTIDE; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGE; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE CALCULATION; DRUG COST; DRUG INTERMITTENT THERAPY; FEMALE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HORMONE BLOOD LEVEL; HUMAN; INDIVIDUALIZATION; MALE; PRIORITY JOURNAL; RADIOTHERAPY; TRANSSPHENOIDAL SURGERY;

ACROMEGALY; ADULT; AGED; AGED, 80 AND OVER; COSTS AND COST ANALYSIS; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL AGENTS; HUMAN GROWTH HORMONE; HUMANS; INJECTIONS, INTRAMUSCULAR; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PROSPECTIVE STUDIES;

EID: 4143086978     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2004.02084.x     Document Type: Article

References (20)

1. Ayuk, J., Clayton, R.N., Sheppard, M.C., Stewart, P.M. & Bates, A.S. (2003) Cerebrovascular Mortality in Acromegaly is increased by the use of external radiotherapy and is not predicted by elevated serum IGF-1. Proceedings of the Endocrine Society.
2. Bates, A.S., Van't Hoff, W., Jones, J.M. & Clayton, R.N. (1993) An audit of outcome of treatment of acromegaly. Quarterly Journal of Medicine, 86, 293-299.
3. Biermasz, N.R. Van den Oevber N.C., Frolich M, Pereira Arias A.M., Smit J.W.A., Romijn J.A. & Roelfsema F. (2003) Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Clinical Endocrinology, 58, 288-295.
4. Caron, P., Tabarin, A., Cogne, M., Chanson, P., Jaquet, P. & Variable, G.H. (2000) profile following withdrawal of long-term 30 mg slow release lanreotide in acromegaly patients: clinical implications. European Journal of Endocrinology, 142, 565-571.
5. Caron, P., Beckers, A., Cullen, D.R., Goth, M.I., Gutt, B., Laurberg, P., Pico, A.M., Valimaki, M. & Zgliczynski, W. (2002) Efficacy of the new long-acting formulation of lanreotide (lanreotide autogel) in the manage,ment of acromegaly. Journal of Clinical Endocrinology and Metabolism, 87, 99-104.
6. Dimaraki, E.V., Jaffe, C.A., DeMott-Friberg, R., Chandler, W.F. & Barkan, A.L. (2002) Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. Journal of Clinical Endocrinology and Metabolism, 87, 3537-3542.
7. Flogstad, A.K., Halse, J., Haldorsen, T., Lancranjan, I., Marbach, P., Bruns, C. & Jervell, J. (1995) Sandostatin LAR in acromegalic patients: a dose-range study. Journal of Clinical Endocrinology and Metabolism, 80, 3601-3607.
8. Freda, P.U., Post, K.D., Powell, J.S. & Wardlaw, S.L. (1998) Evaluation of disease status with sensitive measures of growth hormone secretion in 60 post-operative patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 83, 3808-3816.
9. Grass, P., Marbach, P., Bruns, C. & Lancranjan, I. (1996) Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships. Metabolism, 45, 27-30.
10. James, R.A. & Gilroy, J. (2001) Dose and frequency titration of somatostatin analogues in the treatment of acromegaly - an injection of expediency? Clinical Endocrinology, 54, 11-13.
11. Jenkins, P.J., Akker, S., Chew, S.L., Besser, G.M., Monson, J.P. & Grossman, A.B. (2000) Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clinical Endocrinology, 53, 719-724.
12. Peacey, S.R., Toogood, A.A., Veldhuis, J.D., Thorner, M.O. & Shalet, S.M. (2001) The relationship between 24-hour growth hormone secretion and insulin-like growth factor-1 in patients with successfully treated acromegaly: impact of surgery or radiotherapy. Journal of Clinical Endocrinology and Metabolism, 86, 259-266.
13. Rajasoorya, C., Holdaway, I.M., Wrightson, P., Scott, D.J. & Ibbertson, H.K. (1994) Determinants of clinical outcome and survival in acromegaly. Clinical Endocrinology, 41, 95-102.
14. Sheppard, M.C. (2003) Primary medical therapy for acromegaly. Clinical Endocrinology, 58, 387-399.
15. Stewart, P.M., Kane, K.F., Stewart, S.E., Lancranjan, I. & Sheppard, M.C. (1995) Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. Journal of Clinical Endocrinology and Metabolism, 80, 3267-3272.
16. Stewart, P.M., Stewart, S.E., Clark, P.M. & Sheppard, M.C. (1999) Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR). Clinical Endocrinology, 50, 295-299.
17. Swearingen, B., Barker, EG., Katznelson, L., Biller, B.M., Grinspoon, S., Klibanski, A., Moayeri, N., Black, P.M. & Zervas, N.T. (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism, 83, 3419-3426.
18. Turner, H.E., Vadivale, A., Keenan, J. & Wass, J.A. (1999) A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clinical Endocrinology, 51, 275-280.
19. Vance, M.L. & Harris, A.G. (1991) Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Archives of Internal Medicine, 151, 1573-1578.
20. Wilson, L.S., Shin, J.L. & Ezzat, S. (2001) Longitudinal assessment of economic burden and clinical outcomes in acromegaly. Endocrine Practice, 7, 170-180.